About H2.0-like homeobox protein
H2.0-like homeobox protein (HLX) is a protein
from Homo sapiens identified by UniProt accession
Q14774, 488 residues long.
MolForge cross-references it against 0 known binders and
148 disease associations.
Target properties
| Protein name | H2.0-like homeobox protein |
| UniProt accession | Q14774 |
| Gene | HLX |
| Organism | Homo sapiens |
| Length | 488 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (148)
Diseases linked to this target (Open Targets).
- eosinophil count · score 0.47
- monocyte count · score 0.45
- sex hormone-binding globulin measurement · score 0.45
- neutrophil count · score 0.44
- vital capacity · score 0.44
- monocyte percentage of leukocytes · score 0.43
- leukocyte count · score 0.43
- C-reactive protein measurement · score 0.42
- IGF-1 measurement · score 0.42
- appendicitis · score 0.41
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14774-F1 | alphafold | PREDICTED | 55.36 | — |
Amino-acid sequence (488 residues)
MFAAGLAPFY ASNFSLWSAA YCSSAGPGGC SFPLDPAAVK KPSFCIADIL HAGVGDLGAA PEGLAGASAA ALTAHLGSVH PHASFQAAAR SPLRPTPVVA PSEVPAGFPQ RLSPLSAAYH HHHPQQQQQQ QQPQQQQPPP PPRAGALQPP ASGTRVVPNP HHSGSAPAPS SKDLKFGIDR ILSAEFDPKV KEGNTLRDLT SLLTGGRPAG VHLSGLQPSA GQFFASLDPI NEASAILSPL NSNPRNSVQH QFQDTFPGPY AVLTKDTMPQ TYKRKRSWSR AVFSNLQRKG LEKRFEIQKY VTKPDRKQLA AMLGLTDAQV KVWFQNRRMK WRHSKEAQAQ KDKDKEAGEK PSGGAPAADG EQDERSPSRS EGEAESESSD SESLDMAPSD TERTEGSERS LHQTTVIKAP VTGALITASS AGSGGSSGGG GNSFSFSSAS SLSSSSTSAG CASSLGGGGA SELLPATQPT ASSAPKSPEP AQGALGCL
Explore H2.0-like homeobox protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets